Roche and Spark Therapeutics announced another extension of the Swiss drugmaker’s US$4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews in the United States and Britain continue.
Roche, Spark extend US$4.3 billion takeover again, this time to September 3
